Drug Type Small molecule drug |
Synonyms GL-2504 |
Target |
Mechanism Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (01 Dec 2011), |
Regulation- |
Molecular FormulaC21H30ClNO4 |
InChIKeyZHMPDWYRECUDOQ-BTJKTKAUSA-N |
CAS Registry1258859-73-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anorexia Nervosa | KR | 01 Dec 2011 |
Phase 4 | 14 | Placebo+Sibutramine (Sibutramine) | ltwoeykhjm(lbdaoedlwn) = shskwnjcrw ggumgfwcfa (uvxzqgvhvy, hxbesrfmpj - adnlirugzi) View more | - | 31 Jul 2017 | ||
Placebo+Sibutramine (Placebo) | ltwoeykhjm(lbdaoedlwn) = nxigfaiwji ggumgfwcfa (uvxzqgvhvy, tudzxmvybx - pffotsiezm) View more | ||||||
Phase 4 | 104 | (Sibutramine) | jkglyrzhor(cczirbeysr) = ujnvdwsndp ipcyagvcyq (psrcyfneiy, wjrqvdcegd - gvzwvjjsuk) View more | - | 12 Dec 2014 | ||
Placebo (Placebo) | jkglyrzhor(cczirbeysr) = yayfaccqds ipcyagvcyq (psrcyfneiy, okcizjhhwq - jglbvwemlj) View more |